Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Adding the Multikinase Inhibitor Sorafenib (Nexavar) to Existing Endocrine Therapy in Patients With Advanced Breast Cancer

NCT00525161 is registered in ClinicalTrials.gov with Suleiman Massarweh as lead sponsor.

NCT NCT00525161
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00525161 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Adding the Multikinase Inhibitor Sorafenib (Nexavar) to Existing Endocrine Therapy in Patients With Advanced Breast Cancer
Lead sponsor
Suleiman Massarweh
Phase
Phase 2
Overall status
Terminated
Start date
October 31, 2007
Completion date
January 31, 2015
Enrollment
11 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer